So we also could investigate molecular data in association with PET/CT with other new tracers, such as radiolabelled dihydrotestosterone and radiolabelled antibody to prostate-specific membrane antigen (PSMA)40–42, in order to better define tumour biology, mechanism of treatment resistance and potential therapeutic targets in mCRPC patients. This evidence concerns the gene FOLH1 and neoplasm.